Update on imatinib for gastrointestinal stromal tumors: duration of treatment

Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the gastrointestinal tract, with transformation typically driven by activating mutations of c-KIT and less commonly platelet-derived growth factor receptor alpha (PDGFRA). Successful targeting of c-KIT and PDGFRA with imatinib, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Linch, Mark, Claus, Jeroen, Benson, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735340/
https://www.ncbi.nlm.nih.gov/pubmed/23935374
http://dx.doi.org/10.2147/OTT.S31260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735340/
https://www.ncbi.nlm.nih.gov/pubmed/23935374
http://dx.doi.org/10.2147/OTT.S31260

Ejemplares similares